Kornimate/medical-research-clean huggingface dataset:
taurolidine in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase i trial to study the effectiveness of taurolidine in treating patients who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

objectives: i. determine the maximum tolerated dose and recommended phase ii dose of taurolidine after positive second-look surgery in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. ii. determine the dose-limiting toxicity and safety of this drug in these patients. outline: this is a dose-escalation study. patients receive taurolidine intraperitoneally weekly on weeks 1-3 and 7-9 in the absence of disease progression or unacceptable toxicity. cohorts of 1-6 patients receive escalating doses of taurolidine until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. patients are followed every 3 weeks for 9 weeks. projected accrual: a maximum of 15 patients will be accrued for this study within 12-18 months.

Eligibility criteria:
disease characteristics: histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal adenocarcinoma stage iic or higher at diagnosis successfully received prior chemotherapy undergone initial cytoreductive surgery evidence of gross disease at second-look surgery patient characteristics: age: 18 and over performance status: karnofsky 70-100% life expectancy: not specified hematopoietic: platelet count at least 100,000/mm3 hepatic: bilirubin less than 1.5 mg/dl ast and/or alt less than 3 times upper limit of normal no clinically significant pt/ptt abnormality renal: creatinine less than 1.7 mg/dl other: no known hypersensitivity to taurolidine or its excipients no other clinically significant disease that would preclude study prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics endocrine therapy: not specified radiotherapy: not specified surgery: see disease characteristics other: at least 30 days since prior investigational drugs

Keywords: stage ii ovarian epithelial cancer stage iii ovarian epithelial cancer stage iv ovarian epithelial cancer recurrent ovarian epithelial cancer fallopian tube cancer primary peritoneal cavity cancer
efficacy of a red yeast rice based nutraceutical plus probiotic in patients with moderate hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: a randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy of a red yeast rice based nutraceutical (monacolin k 10 mg/dose) plus probiotic (bifidobacterium longum bb536 ®), versus placebo, in patients with moderate hypercholesterolemia, in terms of improvement of the lipid profile and cardiovascular risk.


Eligibility criteria:
inclusion criteria: * 18 ≤ men or women ≤ 70 * men or female. female must be postmenopausal or surgically sterile * 130 mg/dl ≤ ldl-c ≤ 200 mg/dl * patients in primary cardiovascular prevention exclusion criteria: * pregnancy and lactating * patients with chronic diseases * patients with serious hepatic diseases * patients with serious renal diseases * patients with thyroid diseases * diabetes mellitus or glycemia \>126 mg/dl * uncontrolled or severe hypertension * obesity(bmi\>30) * smoking status * drug or nutraceutical that can interfere with the experimental treatment

Keywords: hypercholesterolemia bifidobacterium longum bb536 red yeast rice monacolin k lactoflorene colesterolo
exercise training and insulin sensitivity

Conditions: Obesity; Exercise

Summary: regular exercise participation is known to reduce cardiometabolic disease risk but the impact that exercise training has on adipose tissue (at) metabolism is poorly understood, particularly in humans. it is well established that exercise training improves whole-body glucose levels and increases insulin sensitivity, and this can occur within one or two weeks. these effects are usually due to adaptations in skeletal muscle, the tissue responsible for the majority of glucose disposal. however, many studies have now determined that exercise training also results in adaptations in at that improve whole-body metabolic health by improving glucose uptake into the at. skeletal muscle is thought to account for approximately 75-85% of glucose uptake , and this process is impaired in .individuals who are insulin-resistant state. it is postulated that the increased level of adiposity that accompanies severe obesity would result in higher dependency on at for glucose uptake as the at would be a bigger "sink". thus the role of at in inducing whole body insulin resistance is still unclear, particularly in individuals with obesity. this study will examine the changes in at glucose uptake before and after 4 weeks of exercise training in obese individuals and establish if there are sex differences.


Eligibility criteria:
inclusion criteria: * non-smokers, weight stable (\<4 kg) within the last 6 months will be recruited for this study. * sedentary (not engaged in planned physical activities and performing less than a total of 2 h of physical activity per week during the last 6 months) men and women whose bmi is classified as obese (\>30 kg/m2). exclusion criteria: * cardiovascular disease, uncontrolled hypertension (no beta blockers), smokers, pregnant, have any recent changes in hormonal birth control, or on any medications known to impact metabolism. * all participants will be regular sleepers with a duration of 7-9 hours/night. * subjects with orthopedic limitations will not be included.
testing conversation aid in practice

Conditions: Breast Cancer

Summary: the goal of this research study is to develop and test a website to help primary care providers (pcps) discuss the pros and cons of mammography with women aged 75 and older and to help participants make decisions about mammography.

this research study is to conduct a pilot pretest-posttest trial to learn if providing a web-based conversation aid (ca) on mammography screening to 36 primary care providers facilitates shared decision making (sdm) and 8 medical assistants with 190 of their patients (2-3 per pcp) aged 75-89 years and 23 involved family members. research procedures include screening for eligibility, questionnaires, and clinic visits. participation in this research study is expected to last about 4 months. it is expected about 90 participants, 23 participant family members, 36 primary care providers, and 8 medical assistants will participant in this research study. the national institute on aging is supporting this research study by providing funding.

Eligibility criteria:
participant inclusion criteria: * english-speaking * aged 75 - 89 years * seen by an attending-level (non-resident) seen at the recruitment practices who have the -ability and willingness to provide verbal consent. participant family members inclusion criteria: * family member of patient that has agreed to participate in the study * age \>18 * english speaking * ability and willingness to provide verbal consent primary care provider inclusion criteria: * non-resident physician, nurse practitioner, or physician assistant -\>18 years old * english speaking * cares for a panel of patients that includes women \>75 years at one of the recruitment practices * ability and willingness to provide verbal consent participant exclusion criteria: * last mammogram \ 30 months (so that participants may be contemplative of their next mammogram) * history of dementia * incapacity for informed consent * history of invasive or non-invasive breast cancer * last mammogram was abnormal * non-english speaking * already chose to stop being screened (documented in medical records or scores of 1-3 \[do not intend to be screened\] on a validate 15 point intentions to be screened scale.) * pcp unwilling to have patient participate * in hospice * pcp not willing to participate * psychiatric illness situations that would limit compliance with study requirements participant family member exclusion criteria: * age \<18 * non-english speaking * psychiatric illness situations that would limit compliance with study requirements primary care provider exclusion criteria: * resident physician * psychiatric illness situations that would limit compliance with study requirements

Keywords: breast cancer mammography breast cancer screening mammography screening
sublay versus intraperitoneal onlay mesh repair in large ventral hernias

Conditions: Ventral Hernia

Summary: the aims of this study is to compare the efficacy of modified sublay hernioplasty versus intraperitoneal onlay mesh repair for large ventral hernias. specifically, this study will assess the primary outcome of recurrence rate one year post surgery and evaluate secondary outcomes, including intraoperative complications, infection rates, pain levels, and post operative hospital stay durations.

in general surgery, the management of ventral abdominal hernias characterized by the protrusion of tissue through weaknesses in the abdominal wall presents significant challenges, particularly when dealing with large ventral hernias, defined as those ≥10 cm or those under tension if closed primarily. incisional hernias, a specific subset of ventral hernias, add to the complexity of repair. while the intraperitoneal onlay mesh (ipom) technique is noted for its reduced surgical and postoperative complications and lower reoperation rates, it also suffers from high costs, limited availability of specialized meshes like dynamesh, and increased intraoperative complications. alternatively, the modified open sublay technique, which employs a primary retro-muscular fascial repair and uses an affordable polypropylene mesh, offers a promising and cost effective solution with potential for a tension free repair. this thesis aims to evaluate and compare these techniques to identify the most effective approach for large ventral hernia repair, balancing surgical outcomes, and complication rates.

Eligibility criteria:
inclusion criteria: * age (18-70) years, both sexes. * fitness for surgery. * patients with uncomplicated ventral hernia. * large anterior abdominal wall defect. exclusion criteria: * patients don't fit for general anesthesia due to sever co-morbidity. * patients with complicated ventral hernia. * patient refusal of surgical intervention. * history of bleeding disorders. * pregnancy in female patients
telemedical coaching for weight loss

Conditions: Overweight; Obesity; Metabolic Syndrome

Summary: lifestyle changes often fail due to loss of motivation. telemedicine and personal coaching have the potential to support lifestyle change and weight loss. therefore, the aim of our randomized controlled trial is to examine the effect of telemedicine with and without coaching in comparison to a control group on weight loss in overweight participants.

in an occupational health care setting employees with overweight and/or metabolic syndrome will be randomized into a three arm 12-week trial. participants in the telemedical (tm) and telemedical coaching (tmc) group got a weighing machine and a step counter, with automatic transfer into a personalized online portal, which could be monitored from both, the participant and the study centre. the tmc group weekly will get care calls from the study centre aiming to discuss measured data and to fix target agreements. the control group will remain in routine care.

Eligibility criteria:
inclusion criteria: * employed at boehringer ingelheim pharma gmbh for at least 2 years * older than 40 years * overweight or obese or metabolic syndrome exclusion criteria: * not willing to participate

Keywords: telemedicine overweight obesity
new treatments for actinic keratoses of the scalp

Conditions: Photodamaged Skin; Actinic Keratoses

Summary: this blinded controlled 2-year study on 120 patients with 2 or more actinic keratoses, compare the efficacy and tolerability of pulsed dye-laser- mediated photodynamic therapy compared to conventional photodynamic therapy and fractional-laser assisted daylight photodynamic therapy compared to daylight photodynamic therapy.

actinic keratoses are premalign skin lesions with increasing prevalence, causing a rising burden on the health care system. in this blinded controlled study we assess the efficacy of pulsed dye-laser- mediated photodynamic therapy compared to conventional photodynamic therapy and fractional-laser assisted daylight photodynamic therapy to daylight photodynamic therapy. it is a prospective, randomized and blinded split-head comparative study during the years 2016- 2024. 120 patients are recruited based on referral or from patients attending the clinic, with 2 or more actinic keratoses on the head, 60 to the pulsed dye-laser study and 60 to the fractional laser study. follow-up appointments are 6 months, 1 year and 2 years post treatment. patient reported maximal pain during treatment is documented.

Eligibility criteria:
inclusion criteria: * at least 2 aks located on both sides of the head (either the scalp, forehead, temples, or cheeks) exclusion criteria: * pigmented aks, in situ-carcinomas, skin cancers, psoriasis or eczema on the treatment area
comparison of buprenorphine and methadone - 3

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to compare agonist and antagonist profile associated with buprenorphine vs. methadone during opiate withdrawal.


Eligibility criteria:
please contact site for information.
brca1/2 flu vaccine

Conditions: BRCA1 Mutation; BRCA2 Mutation

Summary: to evaluate immune function in brca1/2 mutation carriers without cancer, specifically to determine whether immune function in healthy individuals with germline loss of function brca1/2 mutations, impacts overall immune health and fitness.


Eligibility criteria:
inclusion criteria: * males and females * over age 25 * brca1 or brca2 pathogenic or likely pathogenic mutation * no personal cancer history apart from non melanoma skin cancer, localized thyroid cancer, in situ cancers of any type * participants must sign the informed consent form exclusion criteria: * are allergic to influenza vaccination * have received influenza vaccination within the past 6 months * require prednisone, methotrexate, or other immunosuppressing medications * have hiv infection * have a history of solid organ tumor or bone marrow transplant * require combination immunotherapy; * are on other studies requiring blood draws that might exceed 450 ml total during the period of the influenza vaccine study
a study of ridaforolimus in pediatric participants with advanced solid tumors (mk-8669-056)

Conditions: Solid Tumors

Summary: the main objectives of this trial are to determine the recommended dose of ridaforolimus for pediatric participants with advanced solid tumors by measuring the number of participants experiencing dose-limiting toxicities (dlts) while on different doses of ridaforolimus, and to characterize the pharmacokinetics of ridaforolimus in these participants. the primary hypotheses of this study are that 1) the dlts observed will be dose-dependent and allow for definition of a maximum tolerated dose (mtd) and 2) at a safe and well tolerated dose, ridaforolimus geometric mean (gm) day-5 blood area under the concentration-time curve at 24 hours (auc0-24) exceeds 75% (or 1304-ng\*hr/ml) of the estimated gm day-5, 40-mg auc0-24 in adults. study-related visits concluded in august 2013. participants who did not have disease progression, adequately tolerated therapy, and continued to meet eligibility criteria for 6 months after the enrollment period had been completed could continue treatment in an extension phase until they met discontinuation criteria or voluntarily withdrew.


Eligibility criteria:
inclusion criteria: * histologic or cytologic diagnosis of a malignant solid tumor, including tumors of the central nervous system and lymphoma, that have progressed despite standard therapy or for which no effective standard therapy is known. participants who have received standard therapy and continue to have biopsy-proven residual stable disease are eligible * measurable or non-measurable disease * must be able to swallow tablets * performance status: lansky play scale ≥70 for children \<10 years of age; karnofsky score ≥70 for children ≥10 to \<16 years; or eastern cooperative oncology group (ecog) status 0-2 for patients age 16 and older * adequate organ function * for females of reproductive potential, a negative pregnancy test must be documented within 72 hours of receiving the first dose of study medication * participants of reproductive potential must agree to use (or have their partner use) adequate contraception throughout the study, starting with visit 1 through 30 days after the last dose of study drug exclusion criteria: * currently receiving any other investigational agents or using any investigational devices * leukemia * participant previously received ridaforolimus, rapamycin, or other rapamycin analogs * history of allergic reactions attributed to compounds of similar chemical or biologic composition to ridaforolimus * persistent acute toxicity from previous therapy ≥grade 2 (excluding alopecia, neuropathy, or hearing loss) * uncontrolled intercurrent illness despite adequate therapy * pregnant or breastfeeding * requirement for concurrent treatment with medications that are inducers or inhibitors of cytochrome p450 (cyp3a) * poorly controlled type 1 or 2 diabetes
segment transport versus acute shortening in the treatment of tibial pseudarthroses with bone loss

Conditions: TIBIA PSEUDOARTHROSES

Summary: in this study the investigators are presenting the advantages as well as the disadvantages of acute shortening and relengtheninig vs segment transport methods.


Eligibility criteria:
inclusion criteria:tibia pseudoarthroses - exclusion criteria:bone loss greater than 10 cm -
sound ear check (sec) in hearing diagnostics in young children

Conditions: Hearing Loss; Otitis Media With Effusion; Tympanostomy

Summary: study sound ear check (sec) hearing test among 3-10 years old otherwise healthy children referred to tympanostomy tube placement. sec test prior surgery (with middle ear fluid) and at 1 month control visit (dry middle ear with ventilation tube). otitis media 6 questionnaire prior surgery and at the 1 month control visit.

sound ear check (sec) is an automated tablet-based self-test that uses common nonspeech sounds (ecological sounds) that are accompanied by pictures that are easily recognizable even for younger children. before tti operation, each participant will be tested with sec using normal (dichotic) sounds and antiphasic sounds. results will be compared to middle ear findings and the test will be repeated one month after the operation when the middle ears are checked to be dry (with a ventilation tube). at the time of the myringotomy during tti operation, possible middle ear fluid will be classified as serous (transparent, clear), mucous (thick) or purulent (consisting of pus). a tympanometry will be performed within the same visit as the sec measurement before the tti operation. at the time of tympanometric examination, each participant will be classified as cooperative (sittings still, not crying, not resisting) or non-cooperative. tympanometric findings will be classified after the jerger classification. sec and tympanometric testing is designed to be performed at the same visit as tti operation as patients will be waiting for the operation at the ward. medical history of the study patients will be collected from the hospital patient records and through interview and questionnaires to the subjects. ear related quality of life questionnaire (om-6) will be performed at the beginning of the study and the one month control visit. questionnaires are collected using web-based redcap -software (research electronic data capture).

Eligibility criteria:
inclusion criteria: * finnish speaking (child and parent) exclusion criteria: * prior sensorineural hearing loss * developmental disorder * prior ear surgery (except tympanostomy insertion)
methylphenidate treatment for cocaine abuse and adhd - 1

Conditions: Attention Deficit Disorder With Hyperactivity; Cocaine-Related Disorders

Summary: many cocaine dependent individuals are also diagnosed with attention deficit hyperactivity disorder (adhd). methylphenidate (ritalin) is currently approved to treat individuals diagnosed with adhd. the purpose of this study is to determine the effectiveness of methylphenidate in treating adhd symptoms in cocaine dependent individuals.

methylphenidate (mph) is commonly used to treat individuals diagnosed with adhd. the purpose of this study is to determine the effectiveness of mph in treating adult cocaine dependent individuals who are also diagnosed with adhd. participants in this 14-week, double-blind, placebo-controlled study will be randomly assigned to receive either sustained-release mph or placebo. all participants will receive individual cognitive behavioral therapy. the trial will last 14 weeks. it will include a 1-week placebo lead-in phase and a 2-week dose titration phase, followed by 11 weeks on a stable dose of mph. during the titration phase, mph will be given twice a day, starting at a dose of 10 mg/day. the dose will increase by 10 mg each day, until a final stable dose of 40 mg/day is reached. at this time, sustained-release mph will be given as two 20 mg doses (one in the morning and one in the afternoon). depending on a participant's tolerance of mph, the dose will be increased to a maximum of 60 mg/day (40 mg in the morning and 20 mg in the afternoon). participants who are unable to tolerate a dose of at least 40 mg/day of mph will be discontinued from the study. assessments of adhd symptoms will be completed at weekly study visits. in addition, drug use assessments will also be completed and will include self-reports and urine toxicology tests.

Eligibility criteria:
inclusion criteria: * meets dsm-iv criteria for cocaine dependence * meets dsm-iv criteria for persistent adult attention deficit hyperactive disorder exclusion criteria: * meets dsm-iv criteria for current psychiatric disorders (other than adhd or substance abuse) that requires a psychiatric intervention * physiologically dependent on sedatives or alcohol, to the extent that medical attention is required during periods of abstinence or significant reduction in the amount of use * exhibits suicidal or homicidal behavior within the two years prior to enrollment * currently taking prescription psychotropic medication * unstable medical condition (e.g., uncontrolled diabetes) that would make participation in the study hazardous * known sensitivity to methylphenidate * pregnant or breastfeeding

Keywords: adhd cocaine dependence treatment methylphenidate